NAD+ Benefits: Separating What Research Supports From What It Doesn’t
Summarize with AI:
FAQs
The most consistently confirmed NAD+ benefit in human trials is blood NAD+ elevation itself: oral NMN and NR supplementation reliably raises circulating NAD+ levels in humans. Beyond that biomarker confirmation, the most supported specific outcome is improved insulin sensitivity in muscle tissue, established in postmenopausal women with prediabetes in the Yoshino 2021 Science study. Sleep quality improvement in older adults has an emerging positive signal from a 2024 RCT. Some cardiovascular markers have shown positive trends in specific populations. What the aggregate evidence does not clearly confirm is muscle mass and strength improvement in older adults (the 2025 meta-analysis found minimal benefit), broad metabolic improvements (most lipid and glucose outcomes not significantly different from placebo in the Zhang 2025 meta-analysis), or anti-aging effects in the broad sense the term is used in marketing contexts.
The animal-to-human translation gap reflects several real biological differences. Rodents have faster metabolic rates and shorter lifespans, which means interventions that produce effects within weeks in a mouse may require months or years to show effects in humans. Rodent tissue-specific NAD+ metabolism differs from human metabolism in ways that affect how much intracellular NAD+ rises in response to oral supplementation. Additionally, the doses that produce effects in mice, when scaled to human body weight, often exceed what is studied in human trials. And critically, mouse studies can use endpoints like lifespan that are simply not feasible in human clinical trials. The 2026 systematic review by Poon et al. on the biorxiv preprint server concluded that the NMN and NR human trial evidence bases are structurally insufficient to support many of the comparisons and conclusions that have been drawn from them.
This is one of the most frequently claimed NAD+ benefits and one of the most poorly supported in controlled human trials. The mechanistic rationale is solid: NAD+ is essential for mitochondrial ATP production, and cellular energy decline with aging is plausibly connected to falling NAD+ levels. However, a 2023 systematic review in Nutrients examining IV NAD+ supplementation and fatigue outcomes did not find controlled trial evidence confirming the effect versus placebo. Patient-reported improvements in energy following NAD+ therapy are common in clinical settings. These reports cannot rule out a substantial placebo effect without controlled comparison. The absence of an RCT confirming energy benefit does not prove NAD+ does not help with energy. It means the evidence is not at the level required for a confident clinical claim.
Based on the current controlled trial evidence, no. This is one of the more surprising findings from the 2025 evidence review. The meta-analysis published in the Journal of Cachexia, Sarcopenia and Muscle, which examined 10 randomized controlled trials of NMN and NR versus placebo in older adults, concluded that current evidence does not support the use of NMN or NR as effective interventions for improving muscle function and mass in adults over 60. This finding was consistent across the included trials. Importantly, the trials did confirm that NAD+ precursors raised blood NAD+ levels. The muscle outcomes simply did not follow the biomarker change. This does not rule out future positive findings from better-designed or longer trials, particularly in combination with resistance exercise and adequate protein intake. It does mean the current evidence does not support this specific claimed NAD+ benefit.
The 2026 systematic review by Poon et al. conducted a rigorous meta-analysis specifically designed to compare NMN and NR human trial evidence. Its conclusion was that the two evidence bases are structurally too asymmetric to support reliable indirect comparison. The NMN trials were predominantly conducted in East Asian populations, while NR trials were predominantly Western. NR was dosed 1.9 to 9.2 times higher than NMN on a molar basis across trials. The measurement approaches for NAD+ pharmacodynamics were incompatible. In practical terms: both raise blood NAD+ levels in humans. Whether one is clinically superior to the other for any specific outcome cannot be determined from the existing evidence. No head-to-head human trial has been published as of August 2026.
Sirtuins are a family of NAD+-dependent proteins that regulate gene expression, DNA repair, inflammation, and metabolic adaptation. They require NAD+ as a cosubstrate to function. In laboratory and animal models, sirtuin activation has been associated with extended lifespan, improved metabolic function, and reduced inflammation. Raising NAD+ through oral precursors is proposed to support sirtuin activity by providing more of the cosubstrate they require. This is a well-characterized biochemical mechanism. The question that human trials have not yet answered is whether oral NMN or NR at the doses used in supplement protocols raises tissue NAD+ in the specific compartments where sirtuin activity matters most, and whether that elevation is large enough to measurably change sirtuin activity in humans. The biomarker evidence shows blood NAD+ rises. What happens downstream in tissues, and whether sirtuin activation is meaningfully increased, is not yet confirmed in controlled human studies.
NAD+ and GH-stimulating peptides like Sermorelin and Tesamorelin work through entirely different and non-overlapping mechanisms. GH peptides act on the pituitary to stimulate growth hormone production, with downstream effects on lean body mass, fat metabolism, sleep architecture, and recovery. NAD+ addresses the intracellular energy production and genomic maintenance layer. Neither substitutes for the other. In clinical practice, some providers discuss both as part of a comprehensive longevity protocol on the rationale that they address different biological layers of age-related decline. The complementary mechanisms and how these approaches might fit together are covered in depth in the article on NAD+ and Peptide Therapy.
This question comes up because NAD+ is involved in pathways relevant to cellular proliferation. PARP enzymes, which consume NAD+ for DNA repair, play roles in cancer cell survival. Sirtuin activity influences cellular stress responses that interact with tumor suppression pathways. Some animal research has found that in animals that already have cancer, NAD+ boosting compounds may support cancer cell metabolism. The clinical trials of oral NMN and NR in healthy adults have not documented increased cancer risk at the doses and durations studied. However, active malignancy is a consideration that belongs in a conversation with a physician before starting any NAD+ supplementation protocol, particularly at higher doses or through injectable routes. Patients with a personal or strong family history of cancer should discuss NAD+ supplementation with their oncologist or primary care provider rather than initiating it independently.